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1. Introduction
  Dysfunctional uterine bleeding (DUB) includes anovulatory 
dysfunctional uterine bleeding (ADUB) and ovulatory 
dysfunctional uterine bleeding (ODUB). The mechanisms 
underlying ADUB and ODUB remain unclear. Therefore, 
although the current clinical practice based on the age, 
medical history, and menstrual history of the patients, as 
well as on ultrasound and other tests have facilitated the 
diagnosis of ADUB and ODUB, a number of difficulties 
are still encountered during early differential diagnosis. 
The development of proteomics technology provides an 
opportunity as well as possibilities for early screening 
and diagnosis of ADUB and ODUB. Preliminary studies 
successfully screened and identified two serum protein 
markers, namely, serum amyploid protein (SAA) and 
vascular endothelial growth factor (VEGF) associated with 
ADUB. SAA expression is upregulated in ADUB patients, 
whereas VEGF expression is downregulated[1]. In this study, 
the serum protein markers were screened by using surface-
enhanced laser desorption ionization time-of-flight mass 
spectrometry (SELDI-TOF-MS) and compared between 
ADUB and ODUB patients.  
2. Materials and methods
2.1. Materials
  Monoclonal mouse antibodies, including anti-SAA, anti-
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VEGF, anti-vitamin K epoxide reductase (VKOR), and anti-
β-actin, were obtained from Rockland (Gilbertsville, USA). 
A ReverAidTM First-strand cDNA synthesis kit and Master 
Mix were purchased from Promega (Peking, China). SAA, 
VEGF, and VKOR ELISA kits were purchased from Aquatic 
Diagnostics Ltd (Stirling, USA). A PBS IIC protein chip meter 
reader was purchased from Ciphergen Biosystems, Inc. A 
Q-STAR4000 mass spectrometer was purchased from ABI 
Researcher (New York, USA). A Powerbook 2000 scanner was 
purchased from Umax (USA). The primers were designed and 
synthesized by Songon Biotech (Shanghai, China).
2.2. Study subjects 
  The study subjects, Lizu females, included 128 ADUB 
patients, 63 ODUB patients, and 93 healthy women, with 
average ages of (41.83±3.85), (40.66±3.13), and (41.54±3.76) 
years, respectively. The patients were either inpatients or 
outpatients in Hainan Provincial People’s Hospital from 
January 2008 to October 2008. Moreover, no subjects were 
diagnosed with any other diseases.
2.3. Sample collection and processing
  Blood samples (5 mL) were collected during menstrual 
period, mixed with anticoagulants, sterilized, and then 
allowed to stand for 1 h at room temperature. Afterward, 
the samples were centrifuged at 12 000 r/min for 30 min at
4 °C. Sera were collected, packaged, and stored at -80 °C for 
future use. Another set of 5 mL menstrual blood specimens 
were collected, mixed with anticoagulants, sterilized, and 
then allowed to stand for 20 min at room temperature. 
Afterward, the samples were centrifuged at 2 000 r/min for 
30 min at 4 °C. Sera were collected, and the supernates were 
packaged and stored at -80 °C until use.
2.4. Protein chip assay and protein spectrum analysis
  A CM10 protein chip was used to reduce experimental 
error. All samples were simultaneously subjected to SELDI 
detection and analysis. Protein spectra were normalized 
after treatment, and the Biomarker WizardTM 3.2 software 
was used for analysis. The parameters are as follows: peak 
signal-to-noise ratio of 5, minimum frequency threshold of 
10%, cluster mass deviation of 0.3%, and secondary standard 
peak valve signal-to-noise ratio of 2.
2.5. Mass spectrometry
   The treated sera of an equal volume were subjeted 
to tricine-SDS-PAGE gel electrophoresis followed by 
Coomassie blue staining. Then, the differential protein 
bands were cut and analyzed using a NanoESI source 
QSTAR Pulsar I mass spectrometer. The proteins were finally 
identified using peptide-mass fingerprinting and peptide 
sequence tags. Alignments were performed by using an 
online database for proteins (http://www.matrixscience.com).
2.6. Western blotting
  Protein concentration was determined using a bicinchoninic 
acid protein assay kit. Proteins were separated in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gels (10%) and then transferred to a polyvinylidene 
difluoride membrane. The membrane was immunoblotted 
overnight with antibodies to SAA (1:2 000), VEGF (1:2 500), 
and VOKA (1:1 000) at 4 °C. The corresponding secondary 
antibody conjugated with peroxidase and enhanced 
chemiluminence reagents were then added to the protein 
samples to visualize the targeted antigens. The levels of 
SAA, VEGF, and VOKA were assessed using the Labwork 
image analysis software.
2.7. RT-PCR 
  Total RNA was extracted using the TRIzol reagent following 
manufacturer’s instructions (Invitrogen, USA). Total RNA 
(1 毺g) was reverse-transcribed using a ReverAid
TM First-
strand cDNA synthesis kit. Afterward, 2 毺g of cDNA was 
added to the RT-PCR system to evaluate the relative levels 
of β-actin mRNA. PCR was performed using the primers 
shown in Table 1. The following PCR conditions were used: 
95 °C for 5 min, followed by 30 cycles at 95 °C for 30 s, 56 °C 
for 20 s, and 72 °C for 40 s, and a final step of 72 °C for 10 min.
Table 1
List of primers for amplification.
Gene Size (bp) Primer sequence
毬-actin 279 P1: 5'-GGC ATC CAC GAA ACT ACC T-3'
P2: 5'-TCG TCC TCA TAC TGC TCA GG-3'
SAA 496 P1: 5'-CTT GCC AGG TAG ACG C-3'
P2: 5'-TTT TCA GTT GGT CGC G-3'
VEGF 749 P1: 5'-GGA GGC TGG CAA CAT AAC-3'
P2: 5'-TGG CTC TTA AAC TAC TTT T-3'
VKOR 994 P1: 5'-GCA GAC TTC ATT TCC CTT-3'
P2: 5'-TTT GGC TCA CTT GGC A-3'
2.8. ELISA
  The collected sera from different groups were analyzed 
using SAA, VEGF, and VOKA ELISA kits according to 
manufacturer’s instructions.
2.9. Statistical analysis
  Statistical analysis was performed using ANOVA. The 
statistical significance of differences between groups 
was determined using the chi-square test by comparison 
with the control group using the SPSS 11.0 software (IBM 
Corporation). Statistical significance was set at the 0.05 level.
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3. Results
3.1. Serum marker screening and identification of ADUB and 
ODUB
  As shown by the SELDI-TOF-MS results (Figure 1), three 
protein peaks for the ADUB, ODUB, and normal groups 
showed significant differences. The protein peak intensities 
[(11.80±1.52) km/z] for ADUB and ODUB were significantly 
higher than that for the normal groups (P<0.05). The protein 
peak intensities [(13.59±2.85) km/z] for the ODUB and 
control groups were increased, compared with that for ADUB 
(P<0.05). The protein peak intensities [(14.68±3.01) km/z] for 
the ADUB and control groups also increased compared with 
that for ODUB (P<0.05).
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Figure 1. Comparison on serum biomarkers between ADUB and 
ODUB using SELDI-TOF-MS.
*P<0.05 vs control.
  The tricine-SDS-PAGE gel analysis showed two protein 
bands for the normal menstrual serum sample supernates at 
approximately 45 and 18 kD. The ADUB serum samples also 
showed two protein bands at 12 and 18 kD. Furthermore, 
the protein bands for the ODUB serum samples appeared at 
approximately 12 and 45 kD. After gel digestion, the 12, 18, 
and 45 kD protein bands were cut, and mass spectrometry 
for the menstrual serum sample supernates and global 
protein (amino acid) alignments were performed online. The 
12 kD band was identified as SAA, the 18 kD band as VKOR, 
and the 45 kD band as VEGF.
3.2. Expression SAA, VKOR, and VEGF in DUB patients
  Changes in the mRNA level and protein expression of SAA, 
VKOR, and VEGF in the DUB patients were determined 
using ELISA, RT-PCR, and Western blotting. The ELISA 
results (Figure 2) showed that the SAA levels in the ADUB 
and ODUB patients increased compared with that in the 
normal group. Moreover, the VEGF levels decreased in 
the ADUB patients, whereas the VKOR levels decreased 
in ODUB patients. The RT-PCR results (Figure 3) the SAA 
mRNA level in the ADUB and ODUB patients was higher 
than that in the normal group. The VEGF mRNA level in 
the ADUB patients was significantly higher than that of the 
normal and ODUB groups. The VKOR mRNA level in the 
ODUB group was significantly lower than that of the normal 
and ADUB groups. As evidenced by Western blotting, the 
expression of SAA, VKOR, and VEGF proteins in the ADUB, 
ODUB, and normal groups (Figure 4) was identical to their 
mRNA performance.
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Figure 2. Expression of SAA, VEGF, and VKOR in patients with 
ADUB and ODUB.
ELISA was used to analyze the protein concentration. *P<0.05 vs 
control.
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Figure 3. RT-PCR analysis of SAA, VEGF, and VKOR in patients 
with ADUB and ODUB.
(M) DNA 5000 marker consisting of segments with different size (5 000, 
3 000, 2 000, 1 500, 1 000, 750, 500, 300, and 100 bp). (1-3) Healthy 
controls; (4-6) ADUB patients; (7-9) ODUB patients.
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Figure 4. Western blotting analysis of SAA, VEGF, and VKOR 
expression in patients with ADUB and ODUB.
(1-2) Healthy controls; (3-4) ADUB patients; (5-6) ODUB patients.
4. Discussion
  Microarray and serial analyses of gene expression are used 
to indirectly study gene function at the mRNA level in order 
to determine the protein gene function. Gene transcription 
levels do not completely represent the protein expression 
level because of the poor correlation between mRNA 
abundance and tissue protein abundance, particularly for 
low-abundance proteins[2]. Therefore, determination of 
the pathogenesis of a disease at the protein level can be 
used to directly elucidate the underlying mechanisms of 
physiological or pathological conditions. SELDI-TOF-MS is 
a recently developed high-throughput proteomics research 
method that does not require the capture of “all” proteins to 
accurately determine the significant differences in protein 
levels. In addition, this technique does not damage the 
protein samples. Thus, complete samples and soluble matrix 
crystals are used to generate mass signals. The method can 
also be used for direct spot detection using untreated serum, 
urine, or tissue extract samples and can therefore be used in 
a wide range of applications[3-6]. The present study applied 
SELDI-TOF-MS to screen serum protein markers for DUB. 
Three different protein peaks were detected and further 
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identified as SAA, VEGF, and VKOR. ELISA, RT-PCR, and 
Western blotting results confirmed that the SAA expression 
levels were upregulated in the menstrual samples from the 
ADUB and ODUB patients, the VEGF expression levels were 
down-regulated in the menstrual samples from the ADUB 
patients, and the VKOR levels were down-regulated in the 
menstrual samples from the ODUB patients. These results 
suggest that SAA, VEGF, and VKOR are associated with DUB.
  The human SAA gene is located on the short arm of 
chromosome 11. Normally, the levels of SAA, which is 
a stress protein, are low in plasma but increases during 
infection and trauma[7,8]. Numerous studies have reported 
the potential use of SAA as a marker for cancers[9-11]. 
Generally, DUB occur for more than 6 months, and SAA 
would be up-regulated as a result of irregular uterine 
bleeding for extended periods. However, a number of studies 
showed that SAA is not associated with stress response. Cho 
et al. found that SAA expression significantly increased in 
621 cancer patients without non-immune inflammation[12]. 
This finding suggests that SAA expression is related to 
cancers but is not associated with inflammatory responses. 
Therefore, increased SAA levels could be a cause of uterine 
bleeding.
  Uterine bleeding is closely linked to endometrial repair, 
which includes epithelial regeneration and angiogenesis. 
Recent studies have shown that VEGF is involved in the 
menstrual cycle and functions by regulating the proliferation 
and migration of endothelial cells and by stimulating 
neovascularization and repair of the endometrium[13,14]. 
In abnormal situations (ADUB patients), the VEGF levels 
significantly decrease when estrogen is inhibited[15]. 
However, menstrual blood entrainment leads to reduced 
VEGF, which leads to angiogenesis and repaired 
endometrium disorders. Meanwhile, VEGF production is at 
a normal level in ODUB patients, because the luteal phase 
and ovulation are normal. In this study, the VEGF levels in 
the menstrual discharges of ADUB patients were lower but 
were normal in the ODUB patients. This result indicates that 
angiogenesis disorders of the endometrium are important 
risk factors of ADUB.
  Vitamin K (VK), a key factor of the body for thromboplastin, 
functions as a carboxylase cofactor that stimulates the 
conversion of glutamic acid residues to 毭 carboxyl acids 
and acts in combination with Ca2+ to promote blood clotting. 
Vitamin K2, a 3-epoxide of VK, depends on VKOR for 
transformation into VK. The human VKOR gene is located on 
chromosomes 10 and 12. Its coding DNA sequence gene has 
a length of 499 bp and encodes a 163-amino acid protein 
with a molecular weight of 18 kD. In this study, the VKOR 
expression levels in ODUB patients were lower than those of 
the normal and ADUB subjects. Thus, we hypothesize that 
clotting disorders are a major cause of ODUB.
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